19.02.2015 Views

1A9bnbK

1A9bnbK

1A9bnbK

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

***<br />

THE DISEASES − CHAPTER 4<br />

173<br />

4.17 Trachoma<br />

Introduction<br />

Trachoma, caused by infection with Chlamydia trachomatis, accounts for about 3% of all<br />

cases of blindness worldwide (1). Repeated episodes of inflammation and resolution<br />

(precipitated by ocular C. trachomatis infection and occurring over years to decades) generate erate<br />

conjunctival scar that can misdirect the eyelashes to rub on the surface of the eye and damage<br />

the cornea.<br />

Investment case<br />

The global economic cost of trachoma from lost productivity has been estimated at<br />

up to US$ 5 billion annually. 1 Such cost-of-illness estimates must be interpreted ted<br />

with caution, especially when compared with those for other diseases, as they are highly hly<br />

sensitive to methodological assumptions. Clearly, however, trichiasis surgery remains one<br />

of the most cost-effective interventions to combat loss of vision. 2,3 At about US$ 40 per<br />

surgery, it is also very affordable. An early estimate of the backlog of cases (almost 5 million<br />

cases) suggested that US$ 200 million might be needed between 2011 and 2020. 4 This is a<br />

conservative estimate of the backlog, relative to more recent regional estimates. Updated<br />

country-specific estimates are expected in 2015. Thanks in part to a large donation of<br />

azithromycin, preventive chemotherapy is also cost-effective. The pharmaceutical industry<br />

has pledged to donate the medicines necessary to achieve elimination.<br />

Using the latest data available on populations known or thought to be at risk, this report<br />

updates estimates of the cost of delivering those medicines to the people who need them.<br />

Once 80% coverage is achieved (at the latest by 2017) and maintained for a minimum of 3<br />

years (a minimum of 5 years where baseline prevalence of active trachoma exceeds 30%),<br />

mass treatment may be able to be stopped, although stopping decisions may need to be<br />

made on a district-by-district basis. The investment target for preventive chemotherapy<br />

(delivery excluding medicines) during 2015–2020 is about US$ 39 million (US$ 32–46<br />

million) per year. The total amount for this period is slightly higher than an earlier estimate

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!